During the 8th Microbiome Movement – Drug Development Summit, held in London at the end of January, MicrobiomePost asked to Herve Affagard, Chief Executive Officer at MaaT Pharma, to give us an update on the clinical trials (Maat013 and Maat033) and to describe the vision of the company for the future of the microbiome space.
Developing microbiome ecosystem therapies to improve outcomes for patients with liquid tumours
Herve Affagard, Chief Executive Officer at MaaT Pharma, gives us an update on the clinical trials (Maat013 and Maat033) and describes the vision of the company for the future of the microbiome space.
